AFFYMAX INC COM STK USD0.001 (AFFY)

0.07
0.01 11.95
OTC
Prev Close 0.08
Open 0.07
Day Low/High 0.07 / 0.07
52 Wk Low/High 0.05 / 0.11
Volume 42.24K
Exchange OTC
Shares Outstanding 37.49B
Market Cap 2.62M
Div & Yield N.A. (N.A)

Latest News

Pomerantz Law Firm Announces Summary Notice Of Pendency And Proposed Settlement Of Affymax, Inc. Class Action And Settlement Hearing – AFFY

Pomerantz Law Firm Announces Summary Notice Of Pendency And Proposed Settlement Of Affymax, Inc. Class Action And Settlement Hearing – AFFY

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of California, that a hearing will be held on December...

Affymax Reports Second Quarter 2014 Financial Results

Affymax Reports Second Quarter 2014 Financial Results

Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014.

Affymax Board Announces Decision To Dissolve The Company

Affymax Board Announces Decision To Dissolve The Company

Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all...

Affymax And Takeda Announce Termination Of Omontys® (peginesatide) Product Collaboration And License Agreement

Affymax And Takeda Announce Termination Of Omontys® (peginesatide) Product Collaboration And License Agreement

Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys ® (peginesatide) product collaboration and license agreement will terminate...

5 Breakout Stocks Ready to Surge Higher

5 Breakout Stocks Ready to Surge Higher

These stocks look primed to break out and trade higher from current levels.

Commit To Buy Affymax At $1, Earn 45.8% Annualized

Commit To Buy Affymax At $1, Earn 45.8% Annualized

Investors considering a purchase of Affymax Inc stock, but tentative about paying the going market price of $1.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2014 put at the $1 strike, which has a bid at the time of this writing of 30 cents.

4 Hot Stocks to Trade (or Not)

4 Hot Stocks to Trade (or Not)

Here's a look at how some of the most active names on the market today are trading technically.

2 Drug Stocks Under $10 To Pick As Favorites

2 Drug Stocks Under $10 To Pick As Favorites

Chris Lau, Kapitall: If there was a recent mild sell-offs in the stock market, investors would not really notice it. Wide [...]

5 Big Stocks to Trade (or Not)

5 Big Stocks to Trade (or Not)

These heavily traded stocks could have some sort of a technical or fundamental catalyst driving investors' attention.

Affymax Announces Reduction In Force To Align Resources Around Ongoing Product Investigation

Affymax Announces Reduction In Force To Align Resources Around Ongoing Product Investigation

Affymax, Inc. (Nasdaq: AFFY) today announced that it will reduce its workforce as part of a plan to focus the company’s resources on the ongoing investigation of reported hypersensitivity reactions in patients ...

4 Biotech Stocks Under $5 to Watch

4 Biotech Stocks Under $5 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm

Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Lawyers Seek To Restore Investors' Losses And Confidence In Affymax, Announces Deans & Lyons Law Firm LLP

Lawyers Seek To Restore Investors' Losses And Confidence In Affymax, Announces Deans & Lyons Law Firm LLP

Deans & Lyons LLP securities lawyers announced potential claims on behalf of shareholders of Affymax (NASDAQ: AFFY) who purchased or acquired stock from December 8, 2011 until February 22, 2013.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks are poised to break out and trade higher from current levels.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look poised to break out and trade higher from current levels.

A Securities Fraud Class Action Lawsuit Has Been Filed Against Affymax, Inc., Shareholders Are Encouraged To Contact Holzer Holzer & Fistel, LLC

A Securities Fraud Class Action Lawsuit Has Been Filed Against Affymax, Inc., Shareholders Are Encouraged To Contact Holzer Holzer & Fistel, LLC

A class action lawsuit has been filed on behalf of investors who purchased common stock of Affymax, Inc.

Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Affymax, Inc.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet Ratings group would like to highlight 3 stocks pushing the drugs industry lower today, Feb. 25, 2013.

Affymax Is Done. RIP.

Affymax Is Done. RIP.

The Omontys recall is a crippling blow that will be hard to overcome.

Affymax Announces Teleconference And Webcast

Affymax Announces Teleconference And Webcast

Affymax, Inc. (Nasdaq: AFFY) will host a teleconference and webcast at 5:30 a.

Affymax, Takeda Recall Anemia Drug

Affymax, Takeda Recall Anemia Drug

Drug companies Affymax and Takeda issue a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients.

Affymax And Takeda Announce A Nationwide Voluntary Recall Of All Lots Of OMONTYS® (peginesatide) Injection

Affymax And Takeda Announce A Nationwide Voluntary Recall Of All Lots Of OMONTYS® (peginesatide) Injection

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (Takeda) today have decided to voluntarily recall all lots of OMONTYS ® (peginesatide) Injection to the user level as a result of new ...